To support its international expansion and strengthen technology differentiation, ImmunAdd, Inc. today announced that its proprietary next-generation fully synthetic vaccine adjuvant platform has been formally named ImmSygma™ (ImmunAdd Synthetic GlycoMolecule Adjuvants).

The Sygma in the platform name echoes the Greek letter Sigma (Σ), carrying a dual meaning of summation and precision—reflecting both the synergy of combining multiple fully synthetic glycomolecule components into a single adjuvant system, and the batch consistency and quality precision that fully synthetic chemistry delivers. A full explanation of the platform naming is available at Technology > Our Adjuvants.

In addition, the liposomal formulation combining the saponin adjuvant IA-05 and the Toll-like receptor 4 (TLR4) agonist IA-41 has been renamed ImmSygma™ IA-541—a designation derived from the sum of its two constituent molecules.

These designations will be used consistently across the Company’s external documents, technical materials and business communications going forward.